Abstracts Archive - Page 927 of 2425 - ACR Meeting Abstracts

Abstract Number: 2530 • 2019 ACR/ARP Annual Meeting
Safety, Pharmacokinetics, and Pharmacodynamics of a Lyophilized Drug Product of KZR-616, a Selective Inhibitor of the Immunoproteasome
Ben Snyder ¹, Darrin Bomba ², Ken Harvey ², Janet Anderl ², Christopher Kirk ², Jinhai Wang ², R Andrea Fan ² and Niti Goel³, ¹Nucleus Network Pty Ltd, Melbourne, Australia, ²Kezar Life Sciences, SOUTH SAN FRANCISCO, CA, ³Kezar Life Sciences, Duke University School of Medicine, South San Francisco, CA
Background/Purpose: KZR-616, a first-in-class selective inhibitor of the immunoproteasome, is being evaluated for the treatment of multiple autoimmune diseases, including LN and PM/DM. At 30…
Abstract Number: 2531 • 2019 ACR/ARP Annual Meeting
Low Vitamin D Is Associated with Miscarriage and Preterm Birth in SLE with a U-shaped Relationship
Michelle Petri¹ and Jessica Li ¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: In the general population, low vitamin D has been associated with adverse pregnancy outcomes including preterm birth, pre-eclampsia and small for gestational age. In…
Abstract Number: 2532 • 2019 ACR/ARP Annual Meeting
Effect of Treatment on Antiphospholipid Antibodies in SLE
Michelle Petri¹, Laurence Magder ² and Daniel Goldman ³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Unlike primary antiphospholipid syndrome patients, most SLE patients with antiphospholipid antibodies are on one or more treatments for their SLE that might affect levels…
Abstract Number: 2533 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Increases Low C3 in SLE
Michelle Petri¹ and Jessica Li ¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Hydroxychloroquine is considered an immunomodulatory that does not affect serology. Hydroxychloroquine (HCQ) was recently introduced into Japan. In SLE patients who started hydroxychloroquine, there…
Abstract Number: 2534 • 2019 ACR/ARP Annual Meeting
Vitamin D Reduces Cardiovascular Risk Factors in SLE
Michelle Petri¹, Jessica Li ¹ and Daniel Goldman ², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Vitamin D has effects on the cardiovascular system, including decreased renin-angiotensin, decreased insulin resistance, increased vascular relaxation and decreased vascular smooth muscle cell proliferation,…
Abstract Number: 2535 • 2019 ACR/ARP Annual Meeting
Identifying Subgroups of SLE Patients with Differential Responses to a BLyS Inhibitor: Application of a Machine Learning Algorithm to Clinical Trial Data
Mimi Kim¹, Kith Pradhan ¹, Peter Izmirly ², Kenneth Kalunian ³, Leslie Hanrahan ⁴ and Joan Merrill ⁵, ¹Albert Einstein College of Medicine, Bronx, NY, ²New York University School of Medicine, New York, ³University of California at San Diego, San Diego, ⁴Lupus Foundation of America, Washington DC, ⁵Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Given the heterogeneity of systemic lupus erythematosus (SLE), the effect of any intervention is expected to vary. The ability to identify those most and…
Abstract Number: 2536 • 2019 ACR/ARP Annual Meeting
Distribution and Predictors of Whole Blood Hydroxychloroquine Levels in Clinical Rheumatology Practices in the United States
Thierry Dervieux¹, Kelley Brady ¹, Don Thomas ², John Conklin ¹, Eugene Fung ³, Claudia Ibarra ¹ and Michelle Petri ⁴, ¹Exagen, Vista, CA, ²Walter Reed National Military Medical Center, Bethesda, MD, ³Arthritis & Osteoporosis Clinic, Waco, TX, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Therapeutic drug monitoring of whole blood Hydroxychloroquine (HCQ) can help identify patients at risk of flares due to underexposure (e.g. severe non-adherence, < 200…
Abstract Number: 2537 • 2019 ACR/ARP Annual Meeting
Influential Factors in Promoting Treat-to-Target for Systemic Lupus Erythematosus via Empowering Patients: A Cohort Study from China by Smart System of Disease Management (SSDM)
Jianlin Huang¹, Yongfu Wang ², Hua Wei ³, Jing Yang ⁴, Tong Xie ⁵, Hongzhi Wang ⁶, Xiaohan Wang ⁷, Yu Zhang ⁴, Cheng Zhao ⁸, Jinmei Zou ⁴, Fang He ⁹, Jinli Ru ¹⁰, Henglian Wu ¹¹, Guosheng Wang ¹², Lingyun Sun ¹³, Shengqian Xu ¹⁴, Yanjie Hao ¹⁵, Xiangpei Li ¹⁶, Zhijun Li ¹⁷, Bing Wu ¹⁸, Yuhua Jia ¹⁹, Yuan Liu ²⁰, Hui Xiao ²⁰, Fei Xiao ²¹ and Chunde Bao ²², ¹The sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China (People's Republic), ²The First Affiliated Hospital of BaoTou Medical College, Baotou, Nei Mongol, China (People's Republic), ³Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China (People's Republic), ⁴Central Hospital of MianYang, Mianyang, Sichuan, China (People's Republic), ⁵Affiliated hospital of Guangdong medical University, Zhanjiang, Guangdong, China (People's Republic), ⁶JiaXing First Hospital, Jiaxing, Zhejiang, China (People's Republic), ⁷Anyang district hospital, Fuyang, Hainan, China (People's Republic), ⁸The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (People's Republic), ⁹Suining Central Hospital, suining, China (People's Republic), ¹⁰The Second Hospital of Shanxi Medical University, Shanxi, Shanxi, China (People's Republic), ¹¹Dongguan donghua hospital, Dongguan, Guangdong, China (People's Republic), ¹²Anhui Provincial Hospital, Hefei, Anhui, China (People's Republic), ¹³The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China (People's Republic), ¹⁴First Affiliated Hospital of Medical University Of Anhui, Hefei, Anhui, China (People's Republic), ¹⁵Peking University First Hospital; Department of Rheumatology and Clinical Immunology, Beijing, Beijing, China (People's Republic), ¹⁶Anhui Provincial Hospital, Heifei, Anhui, China (People's Republic), ¹⁷The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China (People's Republic), ¹⁸Shanghai Gothic Internet Technology Co., Ltd, Shanghai, China (People's Republic), ¹⁹Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ²⁰Shanghai Gothic Internet Technology Co., Ltd, Shanghai, Shanghai, China (People's Republic), ²¹Shanghai Gothic Internet Technology Co., Ltd., shanghai, China (People's Republic), ²²Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of medicine, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Treating to target is routine in rheumatoid arthritis, but no comparable standard has been defined for SLE. In 2015, the definition of Lupus Low Disease Activity State (LLDAS) was…
Abstract Number: 2538 • 2019 ACR/ARP Annual Meeting
Importance of Serum Phosphatidylserine-Specific Phospholipase A1 (PS-PLA1) as a Novel Disease Activity Biomarker of Systemic Lupus Erythematous
Tetsuji Sawada¹, Makoto Kurano ², Harumi Shirai ³, Yukiko Iwasaki ³, Koichiro Tahara ¹, Haeru Hayashi ¹, Koji Igarashi ⁴, Keishi Fujio ⁵, Junken Aoki ⁶ and Yutaka Yatomi ⁷, ¹Department of Rheumatology, Tokyo Medical University Hospital, Tokyo, Japan, ²Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ⁴Bioscience Division, Research and Development Management Department, TOSOH Corporation, Kanagawa, Japan, ⁵Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, ⁶Laboratory of Molecular and Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Miyagi, Japan, ⁷Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Background/Purpose: Phosphatidylserine-specific phospholipase A1 (PS-PLA1) is a secreted lipase that is proposed to be a producing enzyme for lysophosphatidylserine (LysoPS), which is an emerging lipid…
Abstract Number: 2539 • 2019 ACR/ARP Annual Meeting
Patient Perception of Benefit and Risks Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus (SLE)
Sooyeon Kwon¹, Jessica Farrell ², Sarfaraz Hasni ³ and Shubhasree Banerjee ², ¹The Center For Rheumatology, Loudonville, NY, ²The Center for Rheumatology, LLC, Albany, NY, ³NIAMS, National Institutes of Health, Bethesda, MD
Background/Purpose: Hydroxychloroquine (HCQ) is recommended in all patients with systemic lupus erythematosus (SLE). Studies suggest that a significant proportion of subjects are non-adherent to daily…
Abstract Number: 2540 • 2019 ACR/ARP Annual Meeting
Impact of IL34, IFN-α and IFN-λ1 on Disease Activity of SLE Patients in Egypt
Yasmin Hussein¹ and Yousra Sadeq ¹, ¹Mansoura University Hospital, Mansoura, Egypt
Background/Purpose: SLE is a systemic inflammatory and autoimmune disease. IL-34 plays pivotal roles in the proliferation and differentiation of mononuclear phagocyte cells, osteoclastogenesis and inflammation.…
Abstract Number: 2541 • 2019 ACR/ARP Annual Meeting
Pharmacokinetics of Hydroxychloroquine in Systemic Lupus Erythematosus Patients with Renal Impairment
Naoto Yokogawa¹, Masayuki Hashiguchi ², Yoshiki Nagai ³, Kota Shimada ⁴, Shoji Sugii ¹, Miho Oshima ⁵, Keigo Setoguchi ⁶ and Mikiko Shimizu ⁷, ¹Department of Rheumatic Diseases, Tokyo Metropoitan Tama Medica Center, Fuchu, Japan, ²Division for Evaluation and Analysis of Drug Information, Faculty of Pharmacy, Keio University, Tokyo, Japan, ³Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Fuchu, Japan, ⁴Department of Rheumatic Diseases, Tokyo Metropoitan Tama Medica Center, Fuchu, ⁵Division of Rheumatology, Mitsui Memorial Hospital, Tokyo, Japan, ⁶Tokyo Metropolitan Cancer and Infectious Dease Center Komagome Hospital, Tokyo, Tokyo, Japan, ⁷Department of Drug Metabolism and Pharmacokinetics, Faculty of Pharmaceutical Sciences, Aomori University, Aomori, Japan
Background/Purpose: A low glomerular filtration rate (GFR: < 60 mL/min/1.73 m2) is an established risk of hydroxychloroquine (HCQ) retinopathy and is presumably related to higher…
Abstract Number: 2542 • 2019 ACR/ARP Annual Meeting
An Updated Meta-Analysis of the Efficacy and Safety of Mycophenolate Mofetil in the Induction Treatment of Chinese Patients with Lupus Nephritis
Minlin Zhou¹, Yang yang ², Xiaoyan Han ², Xin Yu ² and Haitao zhang ¹, ¹National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China (People's Republic), ²Shanghai Roche Pharmaceuticals Ltd, Shanghai, China (People's Republic)
Background/Purpose: Achieving clinical remission while reducing toxicity are primary objectives in the treatment of lupus nephritis (LN). Mycophenolate mofetil (MMF) has demonstrated efficacy benefits with…
Abstract Number: 2543 • 2019 ACR/ARP Annual Meeting
Meta-Analysis Examining the Clinical Significance of Monitoring of Hydroxychloroquine Levels in SLE
Shivani Garg¹, Rachna Unnithan ², Karen Hansen ³, Nathalie Costedoat-Chalumeau ⁴ and Christie Bartels ¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²UW- Madison, Madison, ³UW Madison, Madison, ⁴Cochin University Hospital, Paris, France
Background/Purpose: Despite the pivotal role hydroxychloroquine (HCQ) plays in treating SLE, less than 50% of patients take HCQ as prescribed. Nonadherence versus lack of effect…
Abstract Number: 2544 • 2019 ACR/ARP Annual Meeting
Results of the Open-label, Non-randomized 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment with Belimumab in Patients with SLE
Sang-Cheol Bae¹, Richard Dimelow ², Beulah Ji ³, Regina Kurrasch ⁴, Saima Muzaffar ⁵, Raj Punwaney ⁴, David Roth ⁴, Paul Stober ⁴, Yeong-Wook Song ⁶, Wendy Xie ⁴ and Fengchun Zhang ⁷, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²GSK, Stevenage, United Kingdom, ³GSK, Uxbridge, Middlesex, United Kingdom, ⁴GSK, Collegeville, PA, ⁵GSK, Stevenage, Hertfordshire, ⁶Seoul National University Hospital, Seoul, Republic of Korea, ⁷Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (People's Republic)
Background/Purpose: Belimumab is approved as add-on therapy in active, autoantibody-positive SLE. Safety and efficacy up to 13 years has been reported in adults, but potential…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].